ChromaDex (CDXC) 10-Q/A 5 Dec 13 2013 Q1 Quarterly report (amended) Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 30, 2013	9-May-12
Document And Entity Information	'	'
Entity Registrant Name	'ChromaDex Corp.	'
Entity Central Index Key	'0001386570	'
Document Type	'10-Q	'
Document Period End Date	30-Mar-13	'
Amendment Flag	'true	'
Amendment Description	'This Quarterly Report on Form 10-Q/A of ChromaDex Corporation (the “Company”) for the quarterly period ended March 30, 2013 includes restated condensed consolidated balance sheet as of March 30, 2013, condensed consolidated statement of operations and condensed consolidated statement of cash flows for the three months ended March 30, 2013 and restated notes to such condensed consolidated financial statements. This restatement is to reflect a correction in the manner in which the Company has accounted for the sale of the BluScience assets to NeutriSci International, Inc. (“NeutriSci”). The value of the equity and the senior secured convertible note that the Company received from NeutriSci as part of the purchase price were originally accounted for at their stated values which resulted in the Company recognizing a gain on the sale of the BluScience assets. Due to the inability to make a reliably determinable estimate of the fair value of the NeutriSci equity securities and the ultimate collectability of the note received as consideration, management has determined that the proper accounting for the sale transaction is the cost recovery method. Under the cost recovery method, no gain on the sale will be recognized until the Company’s cost basis in the net assets sold has been recovered. In addition, the Company originally accounted for its investment in NeutriSci under the cost method and the Company has now determined that the equity method should have been used. The restatement of the Company’s previously issued condensed consolidated financial statements to reflect its correction in accounting for the sale of BluScience assets to NeutriSci is referred to herein as the “Restatement.” For further information regarding the Restatement, see the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on November 21, 2013 (the “Restatement 8-K”), and for detailed financial information with respect to the Restatement, see Note 2 of the notes to condensed consolidated financial statements included in this Quarterly Report on Form 10-Q/A.	'
Current Fiscal Year End Date	'--12-28	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	99,072,166
Document Fiscal Period Focus	'Q1	'
Document Fiscal Year Focus	'2013	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Mar. 30, 2013	Dec. 29, 2012	Mar. 31, 2012
Current Assets	'	'	'
Cash	$966,576	$520,000	$5,805,179
Trade receivables, less allowance for doubtful accounts and returns March 30, 2013 $18,000; December 29, 2012 $450,000	986,370	1,940,539	'
Non-trade receivable	500,000	'	'
Inventories	1,573,452	5,205,304	'
Prepaid expenses and other assets	453,198	261,297	'
Total current assets	4,479,596	7,927,140	'
Leasehold Improvements and Equipment, net	980,792	936,426	'
Other Noncurrent Assets	'	'	'
Deposits	35,424	34,773	'
Long-term investment in affiliate (Note 4)	2,157,804	'	'
Intangible assets, net	171,218	136,182	'
Total other noncurrent assets	2,364,446	170,955	'
Total assets	7,824,834	9,034,521	'
Current Liabilities	'	'	'
Accounts payable	2,376,208	3,428,233	'
Accrued expenses	789,408	876,158	'
Current maturities of capital lease obligations	98,841	77,259	'
Customer deposits and other	314,468	310,267	'
Deferred rent, current	66,772	71,042	'
Total current liabilities	3,645,697	4,762,959	'
Capital lease obligations, less current maturities	218,952	148,374	'
Deferred rent, less current	118,508	129,859	'
Stockholders' Equity	'	'	'
Common stock, $.001 par value; authorized 150,000,000 shares; issued and outstanding March 30, 2013 96,007,883 and December 29, 2012 92,140,062 shares	96,008	92,140	'
Additional paid-in capital	34,886,353	33,617,801	'
Accumulated deficit	-31,140,684	-29,716,612	'
Total stockholders' equity	3,841,677	3,993,329	'
Total liabilities and stockholders' equity	$7,824,834	$9,034,521	'

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 30, 2013	Dec. 29, 2012
Statement of Financial Position [Abstract]	'	'
Trade receivables, less allowance for doubtful accounts and returns	$18,000	$450,000
Common Stock, Par Value Per Share	$0.00	$0.00
Common Stock, Shares Authorized	150,000,000	150,000,000
Common Stock, Shares, Issued	96,007,883	92,140,062
Common Stock, Shares, Outstanding	96,007,883	92,140,062

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended
	Mar. 30, 2013	Mar. 31, 2012
Income Statement [Abstract]	'	'
Sales	$2,334,566	$1,785,006
Cost of sales	1,661,726	2,389,220
Gross profit (loss)	672,840	-604,214
Operating expenses:	'	'
Sales and marketing	729,424	1,858,662
General and administrative	1,359,901	1,961,912
Operating expenses	2,089,325	3,820,574
Operating loss	-1,416,485	-4,424,788
Nonoperating income (expense):	'	'
Interest income	204	1,199
Interest expense	7,791	8,264
Nonoperating expenses	-7,587	-7,065
Net loss	($1,424,072)	($4,431,853)
Basic and Diluted net loss per common share	($0.02)	($0.05)
Basic and Diluted weighted average common shares outstanding	94,626,120	84,706,196

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (USD $)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning Balance, Amount at Dec. 29, 2012	$92,140	$33,617,801	($29,716,612)	$3,993,329
Beginning Balance, Shares at Dec. 29, 2012	92,140,062	'	'	'
Exercise of stock options, Amount	14	6,755	'	6,769
Exercise of stock options, Shares	13,538	'	'	'
Exercise of warrants, Amount	3,414	713,585	'	716,999
Exercise of warrants, Shares	3,414,283	'	'	'
Share-based compensation, Amount	440	548,212	'	548,652
Share-based compensation, Shares	440,000	'	'	'
Net loss, as restated (Note 2)	'	'	-1,424,072	-1,424,072
Ending Balance, Amount at Mar. 30, 2013	$96,008	$34,886,353	($31,140,684)	$3,841,677
Ending Balance, Shares at Mar. 30, 2013	96,007,883	'	'	'

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Mar. 30, 2013	Mar. 31, 2012
Cash Flows From Operating Activities	'	'
Net loss	($1,424,072)	($4,431,853)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation of leasehold improvements and equipment	79,184	85,422
Amortization of intangibles	4,964	3,391
Share-based compensation expense	351,590	65,987
Loss from disposal of equipment	'	1,879
Changes in operating assets and liabilities:	'	'
Trade receivables	971,153	-676,991
Inventories	164,322	-1,145,295
Prepaid expenses and other assets	-86,181	519,481
Accounts payable	-683,152	816,215
Accrued expenses	-72,190	101,229
Customer deposits and other	4,201	20,109
Deferred rent	-15,621	-15,811
Net cash used in operating activities	-705,802	-4,656,237
Cash Flows From Investing Activities	'	'
Purchases of leasehold improvements and equipment	-7,428	-4,714
Purchase of intangible assets	-40,000	-2,000
Proceeds from sale of assets	500,000	'
Net cash provided by (used in) investing activities	452,572	-6,714
Cash Flows From Financing Activities	'	'
Proceeds from issuance of common stock, net of issuance costs	'	10,070,238
Proceeds from exercise of stock options	6,769	'
Proceeds from exercise of warrants	716,999	'
Principal payments on capital leases	-23,962	-22,260
Net cash provided by financing activities	699,806	10,047,978
Net increase in cash	446,576	5,385,027
Cash Beginning of Period	520,000	420,152
Cash Ending of Period	966,576	5,805,179
Supplemental Disclosures of Cash Flow Information	'	'
Cash payments for interest	7,791	8,264
Supplemental Schedule of Noncash Investing Activity	'	'
Capital lease obligation incurred for the purchase of equipment	116,122	50,786
Supplemental Schedule of Noncash Share-based Compensation	'	'
Stock awards issued for services prior to the period	14,560	'
Changes in stock and warrant awards issued for future services	182,502	'
Supplemental Schedule of Noncash Activities Related to Sale of BlueScience Consumer Product Line	'	'
Assets transferred	3,526,677	'
Liabilities transferred	368,873	'
Carrying value of long-term investment in affiliate, net of $500,000 cash proceeds and $500,000 non-trade receivable	$2,157,804	'

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (Parenthetical) (USD $)	3 Months Ended
	Mar. 30, 2013	Mar. 31, 2012
Statement of Cash Flows [Abstract]	'	'
Cash proceeds	$500,000	'
Non-trade receivable	$500,000	'

Interim_Financial_Statements

Interim Financial Statements	3 Months Ended
	Mar. 30, 2013
Interim Financial Statements	'
Note 1. Interim Financial Statements [Text Block]	'
	The accompanying financial statements of ChromaDex Corporation (the “Company”) and its wholly owned subsidiaries, ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. include all adjustments, consisting of normal recurring adjustments and accruals, that, in the opinion of the management of the Company, are necessary for a fair presentation of the Company’s financial position as of March 30, 2013 and results of operations and cash flows for the three months ended March 30, 2013 and March 31, 2012. These unaudited interim financial statements should be read in conjunction with the Company’s audited financial statements and the notes thereto for the year ended December 29, 2012 appearing in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “Commission”) on March 29, 2013. Operating results for the three months ended March 30, 2013 are not necessarily indicative of the results to be achieved for the full year ending on December 28, 2013. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.
	The balance sheet at December 29, 2012 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.

Restatement_of_Previously_Issu

Restatement of Previously Issued Financial Statements	3 Months Ended
	Mar. 30, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Note 2. Restatement of Previously Issued Financial Statements	'
	On November 18, 2013, during the review of the interim financial statements, the Company determined that the previously issued financial statements for the three month period and the six month period ending March 30, 2013 and June 29, 2013, respectively, contained in the Company’s Quarterly Reports on Form 10-Q (“ Quarterly Reports”) for the period ended March 30, 2013 (as filed with the Securities and Exchange Commission on May 10, 2013) and June 29, 2013 (as filed with the Securities and Exchange Commission on August 13, 2013), respectively, should no longer be relied upon because of certain non-cash errors in the Quarterly Reports and that those financial statements (the “Financial Statements”) would be restated to make the necessary accounting adjustments.
	The financial statements filed for the three month period ended March 30, 2013 and the six month period ended June 29, 2013 contained a misstatement pertaining to the accounting treatment of the sale of the BluScience assets to NeutriSci International, Inc. (“NeutriSci”) (See Note 4). The value of the equity and the senior secured convertible note that the Company received from NeutriSci as part of the purchase price were originally accounted for at their stated values which resulted in the Company recognizing a gain on the sale of the BluScience assets. Due to the inability to make a reliably determinable estimate of the fair value of the NeutriSci equity securities and the ultimate collectability of the note received as consideration, management has determined that the proper accounting for the sale transaction is the cost recovery method. Under the cost recovery method, no gain on the sale will be recognized until the Company’s cost basis in the net assets sold has been recovered. In addition, the Company originally accounted for its investment in NeutriSci under the cost method where it has now been determined that the equity method should have been used. The Company expects all amendments and restatements to the Financial Statements affected to be non-cash in nature.
	The Company has determined that the restatements of its Financial Statements resulted from a material weakness in its internal control over financial reporting, specifically related to its process and procedures related to the accounting for sale of assets in exchange for non-cash consideration. More information regarding the Company’s controls and procedures is set forth in Part I, Item 4 of this Form 10-Q/A.
	The restatement adjustments to the previously issued financial statements for the three month period ended March 30, 2013 are as follows:
	ChromaDex Corporation and Subsidiaries
	Condensed Consolidated Balance Sheet (Unaudited)
	30-Mar-13
		Previously			Restatement			As Restated
		Reported			Adjustments
	Assets
	Current Assets
	Cash	$	966,576		$	—		$	966,576
	Trade receivables		986,370			—			986,370
	Non-trade receivable		500,000			—			500,000
	Note receivable, current		1,210,407			(1,210,407	)		—
	Inventories		1,573,452			—			1,573,452
	Prepaid expenses and other assets		453,198			—			453,198
	Total current assets		5,690,003			(1,210,407	)		4,479,596
	Leasehold Improvements and Equipment, net		980,792			—			980,792
	Other Noncurrent Assets
	Deposits		35,424			—			35,424
	Note receivable, less current		1,161,162			(1,161,162	)		—
	Long-term equity investment		2,678,832			(2,678,832	)		—
	Long-term investment in affiliate		—			2,157,804			2,157,804
	Intangible assets, net		171,218			—			171,218
	Total other noncurrent assets		4,046,636			(1,682,190	)		2,364,446
	Total assets	$	10,717,431		$	(2,892,597	)	$	7,824,834
	Liabilities and Stockholders' Equity
	Current Liabilities
	Accounts payable	$	2,376,208		$	—		$	2,376,208
	Accrued expenses		789,408			—			789,408
	Current maturities of capital lease obligations		98,841			—			98,841
	Customer deposits and other		314,468			—			314,468
	Deferred rent, current		66,772			—			66,772
	Total current liabilities		3,645,697			—			3,645,697
	Capital lease obligations, less current maturities		218,952			—			218,952
	Deferred rent, less current		118,508			—			118,508
	Stockholders' Equity
	Common stock		96,008			—			96,008
	Additional paid-in capital		34,886,353			—			34,886,353
	Accumulated deficit		(28,248,087	)		(2,892,597	)		(31,140,684	)
	Total stockholders' equity		6,734,274			(2,892,597	)		3,841,677
	Total liabilities and stockholders' equity	$	10,717,431		$	(2,892,597	)	$	7,824,834
	ChromaDex Corporation and Subsidiaries
	Condensed Consolidated Statement of Operations (Unaudited)
	For the Three Month Period Ended March 30, 2013
		Previously Reported			Restatement			As Restated
					Adjustments
	Sales	$	2,334,566		$	—		$	2,334,566
	Cost of sales		1,661,726			—			1,661,726
	Gross profit		672,840			—			672,840
	Operating expenses:
	Sales and marketing		729,424			—			729,424
	General and administrative		1,359,901			—			1,359,901
	Gain on sale of assets		(2,891,917	)		2,891,917			—
	Operating expenses		(802,592	)		2,891,917			2,089,325
	Operating income (loss)		1,475,432			(2,891,917	)		(1,416,485	)
	Nonoperating income (expense):
	Interest income		884			(680	)		204
	Interest expense		(7,791	)		—			(7,791	)
	Nonoperating expenses		(6,907	)		(680	)		(7,587	)
	Net income (loss)	$	1,468,525		$	(2,892,597	)	$	(1,424,072	)
	Basic net income (loss) per common share	$	0.02		$	(0.03	)	$	(0.02	)
Diluted net income (loss) per common share	$	0.01		$	(0.03	)	$	(0.02	)
Basic weighted average common shares outstanding		94,626,120			—			94,626,120
Diluted weighted average common shares outstanding		97,924,457			(3,298,337	)		94,626,120
ChromaDex Corporation and Subsidiaries
Condensed Consolidated Statement of Cash Flows (Unaudited)
For the Three Month Period Ended March 30, 2013
	Previously Reported			Restatement			As Restated
				Adjustments
Cash Flows From Operating Activities
Net income (loss)	$	1,468,525		$	(2,892,597	)	$	(1,424,072	)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation of leasehold improvements and equipment		79,184			—			79,184
Amortization of intangibles		4,964			—			4,964
Share-based compensation expense		351,590			—			351,590
Gain on sale of assets		(2,891,917	)		2,891,917			—
Interest added to note receivable		(680	)		680			—
Changes in operating assets and liabilities:
Trade receivables		971,153			—			971,153
Inventories		164,322			—			164,322
Prepaid expenses and other assets		(86,181	)		—			(86,181	)
Accounts payable		(683,152	)		—			(683,152	)
Accrued expenses		(72,190	)		—			(72,190	)
Customer deposits and other		4,201			—			4,201
Deferred rent		(15,621	)		—			(15,621	)
Net cash used in operating activities		(705,802	)		—			(705,802	)
Cash Flows From Investing Activities
Purchases of leasehold improvements and equipment		(7,428	)		—			(7,428	)
Purchase of intangible assets		(40,000	)		—			(40,000	)
Proceeds from sale of assets		500,000			—			500,000
Net cash provided by investing activities		452,572			—			452,572
Cash Flows From Financing Activities
Proceeds from exercise of stock options		6,769			—			6,769
Proceeds from exercise of warrants		716,999			—			716,999
Principal payments on capital leases		(23,962	)		—			(23,962	)
Net cash provided by financing activities		699,806			—			699,806
Net increase in cash		446,576			—			446,576
Cash Beginning of Period		520,000			—			520,000
Cash Ending of Period	$	966,576		$	—		$	966,576

Nature_of_Business_and_Signifi

Nature of Business and Significant Accounting Policies	3 Months Ended
	Mar. 30, 2013
Nature Of Business And Significant Accounting Policies	'
Note 3. Nature of Business and Significant Accounting Policies [Text Block]	'
	Nature of business: The Company is a natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The Company supplies ingredients, phytochemical reference standards and related phytochemical products and services. On December 3, 2012, the Company acquired Spherix Consulting, Inc. (“Spherix”), which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage potential health and regulatory risks. The Company provides these products and services at various terms.
	Basis of presentation: The financial statements and accompanying notes have been prepared on a consolidated basis and reflect the consolidated financial position of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated from these financial statements. The Company's fiscal year ends on the Saturday closest to December 31, and the Company’s normal fiscal quarters end on the Saturday 13 weeks after the last fiscal year end or fiscal quarter end. Every fifth or sixth fiscal year, the inclusion of an extra week occurs due to the Company’s floating year-end date. The fiscal year 2014 will include 53 weeks instead of the normal 52 weeks.
	Trade accounts receivable: Trade accounts receivable are carried at original invoice amount less an estimate made for doubtful receivables based on monthly and quarterly reviews of all outstanding amounts. Management determines the allowance for doubtful accounts by identifying troubled accounts and by using historical experience applied to an aging of accounts. The allowances for doubtful accounts for the periods ended March 30, 2013 and December 29, 2012 were $18,000 and $450,000, respectively. Of the allowance amount of $450,000 for the period ended December 29, 2012, $433,000 represents a hold on the receivables placed by a retailer that carried the Company’s BluScience retail consumer line. The hold was placed by the retailer as an offset in the event of future returns of the Company’s products and the hold was treated as a reduction of revenue. On March 28, 2013, the Company sold the BluScience retail consumer line to NeutriSci and the related trade accounts receivable including the allowance have been transferred to NeutriSci. Trade accounts receivable are written off when deemed uncollectible. Recoveries of trade accounts receivable previously written off are recorded when received.
	Inventories: Inventories are comprised of raw materials, work-in-process and finished goods. They are stated at the lower of cost, determined by the first-in, first-out method (FIFO) method, or market. The inventory on the balance sheet is recorded net of valuation allowances of $217,000 and $366,000 for the periods ended March 30, 2013 and December 29, 2012, respectively. Labor and overhead has been added to inventory that was manufactured or characterized by the Company. On March 28, 2013, the Company sold the BluScience retail consumer line to NeutriSci and related dietary supplements inventory have been transferred to NeutriSci. The amounts of major classes of inventory as of March 30, 2013 and December 29, 2012 are as follows:
		30-Mar-13		29-Dec-12
	Reference standards	$	1,598,277	$	1,614,755
	Bulk ingredients		192,175		432,230
	Dietary supplements – raw materials		—		401,809
	Dietary supplements – work in process		—		465,253
	Dietary supplements – finished goods		—		2,657,257
			1,790,452		5,571,304
	Less valuation allowance		217,000		366,000
		$	1,573,452	$	5,205,304
	Earnings per share: Potentially dilutive common shares consist of the incremental common shares issuable upon the exercise of common stock options and warrants for all periods. For the three-month periods ended March 30, 2013 and March 31, 2012, the basic and diluted shares reported are equal because the common share equivalents are anti-dilutive due to the net loss. Below is a tabulation of the potentially dilutive securities that were “in the money” for the three- month periods ended March 30, 2013 and March 31, 2012.
		Three Months Ended
		30-Mar-13		31-Mar-12
	Basic weighted average common shares outstanding		94,626,120		84,706,196
	Warrants and options in the money, net		3,298,337		6,583,163
	Weighted average common shares outstanding assuming dilution		97,924,457		91,289,359
	Total warrants and options that were not “in the money” at March 30, 2013 and March 31, 2012 were 12,338,106 and 18,579,518, respectively.
	Long-term investment in affiliate: The Company accounts for its investment in affiliate under the equity method. The Company records equity method adjustments in gains (losses) on equity method investments, net, and may do so with up to a three-month lag, pending on the timely availability of financial information of the investee. Equity method adjustments include: our proportionate share of investee income or loss, gains or losses resulting from investee capital transactions, and other adjustments required by the equity method. The long-term investment in affiliate is subject to a periodic impairment review and is considered to be impaired when a decline in carrying value is judged to be other-than-temporary. Evidence of a loss in value might include (i) absence of an ability recover the carrying amount of the investment or (ii) inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment.

Sale_of_Product_Line_and_Inves

Sale of Product Line and Investment in Affiliate	3 Months Ended
	Mar. 30, 2013
Sale Of Product Line And Investment In Affiliate	'
Note 4. Sale of Product Line and Investment in Affiliate	'
	On March 28, 2013, the Company entered into an asset purchase and sale agreement with NeutriSci and consummated the sale of BluScience consumer product line to NeutriSci. The Company is using the cost recovery method to account for the sale transaction, which is estimated at approximately $3,157,804. The consideration received consists of following: (a) a $250,000 cash payment, which NeutriSci paid as a deposit in February 2013; (b) an additional $250,000 cash payment, which was paid at the closing of the sale; (c) an additional cash payment of $500,000 due no later than 60 days after the closing of the sale; (d) a $2,500,000 senior convertible secured note (convertible into 625,000 shares Series I Preferred Stock as described below) payable in quarterly installments of $416,667 beginning August 15, 2013; and (e) 669,708 shares of Series I Preferred Shares that are convertible into 2,678,832 Class “A” common shares of NeutriSci, representing an aggregate of 19% of the NeutriSci shares at a deemed price for each Class A common share of $1.00 per share. The transaction documents contain certain equity blockers that preclude the Company’s ownership in NeutriSci in excess of 9.99% and 19% without obtaining a waiver from NeutriSci. The Company will continue to generate revenue through a royalty on 6% of future net sales of BluScience products as well as a supply agreement with NeutriSci for the Company’s patented pTeroPure pterostilbene. As of March 30, 2013, the Company did not have any sales to NeutriSci under this supply agreement for pTeroPure pterostilbene.
	The Company has applied the equity method of accounting for the 669,708 shares of Series I Preferred Shares that are convertible into 2,678,832 Class “A” common shares of NeutriSci and the carrying value, which includes the senior convertible secured note, is reflected as long-term investment in affiliate in the Company’s consolidated balance sheet as of March 30, 2013. The initial carrying value of this investment recognized, as restated, as of March 28, 2013 was $2,157,804, which is the Company’s unrecovered cost or the difference between the net assets transferred to NeutriSci and the initial monetary consideration received. Although, (i) other contemporaneous third party investments in NeutriSci’s Class “A” common shares were $1.00 per share and (ii) the face value of the senior convertible secured note was $2,500,000, management believed that $2,157,804 was the appropriate aggregate carrying value for the investment in affiliate, considering the fact that NeutriSci is a start-up company and has historically recorded significant operating losses. The Company is unable to determine NeutriSci’s likelihood of repaying the note, and because of this significant uncertainty, the amount of collectability of the senior convertible secured note is not ascertainable. There is a significant uncertainty in the realization of value of the Series I Preferred Shares as well. Consequently, management deemed it appropriate to consider that both the 669,708 shares of Series I Preferred Shares and the senior convertible secured note as one long term investment in affiliate. Under the cost recovery method, no gain on the sale will be recognized until the Company’s cost basis in the net assets transferred has been recovered. Prospective collection of payments under the note will be charged against the carrying value of the long-term investment in affiliate. The below table illustrates how the carrying value was determined.
		At March 28, 2013
	Assets transferred
	Trade receivables, less allowance for returns	$	(16,984	)
	Inventories		3,467,530
	Prepaid expenses and other assets		76,131
	Total assets transferred		3,526,677
	Liabilities transferred
	Accounts payable		368,873
	Total liabilities transferred		368,873
	Total net assets transferred	$	3,157,804
	Initial monetary consideration received
	Cash	$	500,000
	Non-trade receivable		500,000
	Total initial monetary consideration received	$	1,000,000
	Carrying Value of Long Term Investment in Affiliate	$	2,157,804
	For the three months ended March 30, 2013, the Company did not record equity method adjustments in gains (losses) on the investment in NeutriSci, as the Company has elected to record equity method adjustments with a three-month lag, as the financial information of NeutriSci was not available in a timely manner. When the financial information is available at a later time, the Company will use NeutriSci’s financial statements for the period beginning on April 1, 2013. This will not cover the three-day period from March 28, 2013 to March 30, 2013, which is also a portion of the Company’s investment period since the Company’s investment started from March 28, 2013. However, the Company has determined that the amount of any impact to the Company for the three day period not covered was immaterial as NeutriSci did not have any significant transactions.
	The cash payment of $500,000 that is due no later than 60 days after the closing of the sale is reflected as non-trade receivable in the Company’s consolidated balance sheet as of March 30, 2013.
	The senior secured convertible note is secured by the Security Agreement, dated March 28, 2013 entered into between the Company and NeutriSci whereby NeutriSci granted the Company a security interest in substantially all of NeutriSci’s assets, including inventory, to secure its obligations pursuant to the note. In the event of default, the note can also be convertible into Series I Preferred Shares of NeutriSci at the option of ChromaDex. Each Series I Preferred Share can be convertible into 4 Class A common shares of NeutriSci. The conversion price will be (a) $4.00 per Series I Preferred Share prior to a Public Offering (as defined in the note); or (b) the closing price of Series I Preferred Share or four times the closing price of Class A common share on a stock exchange immediately prior to the conversion date.
	Under the asset purchase and sale agreement entered into as of March 28, 2013 with the Company, NeutriSci is obligated to file an initial public offering prospectus with a securities commission in Canada no later than September 24, 2013 (or 180 days from the closing date of March 28, 2013) and to concurrently seek approval of the listing of its common shares on the TSX Venture Exchange or similar stock exchange in Canada.
	As of March 30, 2013, the Company has determined that there is no other-than-temporary impairment, as the Company is not aware of any other-than-temporary impairment triggering events or indicators. The Company will continue to monitor NeutriSci’s performance and evaluate if there are any such events or indicators to consider.

Leasehold_Improvements_and_Equ

Leasehold Improvements and Equipment	3 Months Ended
	Mar. 30, 2013
Leasehold Improvements And Equipment	'
Note 5. Leasehold Improvements and Equipment	'
	Leasehold improvements and equipment consisted of the following:
		March 30,		December 29,
		2013		2012
	Laboratory equipment	$	2,563,238	$	2,439,688
	Leasehold improvements		403,971		403,971
	Computer equipment		363,739		363,739
	Furniture and fixtures		18,313		18,313
	Office equipment		7,877		7,877
	Construction in progress		106,080		106,080
			3,463,218		3,339,668
	Less accumulated depreciation		2,482,426		2,403,242
		$	980,792	$	936,426

Employee_ShareBased_Compensati

Employee Share-Based Compensation	3 Months Ended
	Mar. 30, 2013
Employee Share-Based Compensation	'
Note 6. Employee Share-Based Compensation [Text Block]	'
	Stock Option Plans
	At the discretion of the Company’s compensation committee (the “Compensation Committee”), and with the approval of the Company’s board of directors (the “Board of Directors”), the Company may grant options to purchase the Company’s common stock to certain individuals from time to time. Management and the Compensation Committee determine the terms of awards which include the exercise price, vesting conditions and expiration dates at the time of grant. Expiration dates for stock options are not to exceed 10 years from their date of issuance. The Company, under its Second Amended and Restated 2007 Equity Incentive Plan, is authorized to issue stock options that total no more than 20% of the shares of common stock issued and outstanding, as determined on a fully diluted basis.  Beginning in 2007, stock options were no longer issuable under the Company’s 2000 Non-Qualified Incentive Stock Plan.  The remaining amount available for issuance under the Second Amended and Restated 2007 Equity Incentive Plan totaled 6,232,513 at March 30, 2013. The stock option awards generally vest ratably over a four-year period following grant date after a passage of time.  However, some stock option awards are performance based and vest based on the achievement of certain criteria established by the Compensation Committee, subject to approval by the Board of Directors.
	The fair value of the Company’s stock options was estimated at the date of grant using the Black-Scholes based option valuation model.  The table below outlines the weighted average assumptions for options granted to employees during the three months ended March 30, 2013.
	Three Months Ended March 30, 2013
	Volatility		32.64	%
	Expected dividends		0	%
	Expected term	6.1 years
	Risk-free rate		1.13	%
	The Company calculated expected volatility from the volatility of publicly held companies in similar industries, as the historical volatility of the Company’s common stock does not cover the period equal to the expected life of the options.  The dividend yield assumption is based on the Company’s history and expectation of future dividend payouts on the common stock.  The risk-free interest rate is based on the implied yield available on U.S. treasury zero-coupon issues with an equivalent remaining term.  The expected term of the options represents the estimated period of time until exercise and is based on historical experience of awards, giving consideration to the contractual terms, vesting schedules and expectations of future employee behavior.  The estimation process for the fair value of performance based stock options was the same as for service period based options.
	1) Service Period Based Stock Options
	The majority of options granted by the Company are comprised of service based options granted to employees.  These options vest ratably over a defined period following grant date after a passage of a service period.
	The following table summarizes service period based stock options activity at March 30, 2013 and changes during the three months then ended:
					Weighted Average
							Remaining		Aggregate
		Number of			Exercise		Contractual		Intrinsic
		Shares			Price		Term		Value
	Outstanding at December 29, 2012		12,202,558		$	1.08
	Options Granted		230,000			0.63
	Options Exercised		(13,538	)		0.5
	Options Expired		(75,000	)		0.5
	Options Forfeited		(112,530	)		1.37
	Outstanding at March 30, 2013		12,231,490		$	1.08		8.09	$	217,915
	Exercisable at March 30, 2013		5,096,949		$	1.26		6.41	$	113,085
	The aggregate intrinsic values in the table above are before income taxes, based on the Company’s closing stock price of $0.71 on the last day of business for the period ended March 30, 2013.  The weighted average fair value of options granted during the three months ended March 30, 2013 and March 31, 2012 was $0.22 and $0.31 respectively.  The aggregate intrinsic value for options exercised during the three months ended March 30, 2013 was $2,437.  There were no options exercised during the three months ended March 31, 2012.
	2) Performance Based Stock Options
	The Company also grants stock option awards that are performance based and vest based on the achievement of certain criteria established from time to time by the Compensation Committee.  If these performance criteria are not met, the compensation expenses are not recognized and the expenses that have been recognized will be reversed.
	The following table summarizes performance based stock options activity at March 30, 2013 and changes during the three months then ended:
					Weighted Average
							Remaining		Aggregate
		Number of			Exercise		Contractual		Intrinsic
		Shares			Price		Term		Value
	Outstanding at December 29, 2012		145,834		$	1.59
	Options Granted		200,000			0.63
	Options Exercised		-			-
	Options Expired		-			-
	Options Forfeited		(45,834	)		1.59
	Outstanding at March 30, 2013		300,000		$	0.95		9.25	$	16,000
	Exercisable at March 30, 2013		45,834		$	1.59		8.1	$	-
	The aggregate intrinsic value in the table above are before income taxes, based on the Company’s closing stock price of $0.71 on the last day of business for the period ended March 30, 2013.  The weighted average fair value of options granted during the three months ended March 30, 2013 was $0.22.  The Company did not grant any performance based stock options during the three months ended March 31, 2012.
	As of March 30, 2013, there was $2,201,293 of total unrecognized compensation expense related to non-vested share-based compensation arrangements granted under the plans for employee stock options. That cost is expected to be recognized over a weighted average period of 2.39 years as of March 30, 2013.  The realized tax benefit from stock options for the three months ended March 30, 2013, and March 31, 2012 was $0, based on the Company’s full valuation allowance against its deferred tax assets.
	Restricted Stock
	Restricted stock awards granted by the Company to employees have vesting conditions that are unique to each award.
	The following table summarizes activity of restricted stock awards granted to employees at March 30, 2013 and changes during the three months then ended:
					Weighted Average
					Award-Date
		Shares			Fair Value
	Unvested shares at December 29, 2012		500,000		$	0.69
	Granted		-			-
	Vested		-			-
	Forfeited		-			-
	Unvested shares at March 30, 2013		500,000		$	0.69
	Expected to Vest as of March 30, 2013		500,000		$	0.69
	As of March 30, 2013, the Company did not have any unrecognized compensation expense related to restricted stock awards to employees.
	For employee share-based compensation, the Company recognized share-based compensation expense of $286,534 in general and administrative expenses in the statement of operations for the three months ended March 30, 2013.  The Company recognized income of $296,135 in share-based compensation for the comparable period in 2012.  The income amount is a result of certain expenses that were reversed due to the forfeiture of certain stock options and restricted stock.

NonEmployee_ShareBased_Compens

Non-Employee Share-Based Compensation	3 Months Ended
	Mar. 30, 2013
Non-Employee Share-Based Compensation	'
Note 7. Non-Employee Share-Based Compensation [Text Block]	'
	Stock Option Plans
	At the discretion of management, working with the Compensation Committee, and with approval of the Board of Directors, the Company may grant options to purchase the Company’s common stock to certain individuals from time to time who are not employees of the Company.  These options are granted under the Second Amended and Restated 2007 Equity Incentive Plan of the Company and are granted on the same terms as those being issued to employees.  Stock options granted to non-employees are accounted for using the fair value approach.  The fair value of non-employee option grants are estimated using the Black-Scholes option-pricing model and are re-measured over the vesting term until earned.  The estimated fair value is expensed over the applicable service period.
	The following table summarizes activity of stock options granted to non-employees at March 30, 2013 and changes during the three months then ended:
				Weighted Average
						Remaining		Aggregate
		Number of		Exercise		Contractual		Intrinsic
		Shares		Price		Term		Value
	Outstanding at December 29, 2012		1,097,300	$	1.23
	Options Granted		-		-
	Options Exercised		-		-
	Options Forfeited		-		-
	Outstanding at March 30, 2013		1,097,300	$	1.23		5.01	$	59,200
	Exercisable at March 30, 2013		1,096,675	$	1.23		5.01	$	59,069
	The aggregate intrinsic values in the table above are before income taxes, based on the Company’s closing stock price of $0.71 on the last day of business for the period ended March 30, 2013.
	As of March 30, 2013, there was $219 of total unrecognized compensation expense related to unvested share-based compensation arrangements granted to non-employees. That cost is expected to be recognized over a weighted average period of 1.4 months as of March 30, 2013.
	Stock Awards
	From time to time, the Company awards shares of its common stock to non-employees for services provided or to be provided.  If the fair value of services received is more reliably measurable than the fair value of the stock awarded, the fair value of the services received is used to measure the award.  In contrast, if the fair value of the stock issued is more reliably measurable, than the fair value of services received, the award is measured based on the fair value of the stock awarded.  Since these stock awards are fully vested and non-forfeitable, upon issuance the measurement date for the award is usually reached on the date of the award.  The measured fair value of the award is amortized over the period the service is provided.
	During the three months ended March 30, 2013, the Company awarded an aggregate of 440,000 shares of the Company’s common stock to non-employees.  The fair values of the awards were based on the trading price of the Company’s stock on the date of issuance. The expense the Company recognized for stock awards was $62,178 for the three months ended March 30, 2013.  As of March 30, 2013, there was $204,746 of total unrecognized compensation expense related to stock awarded to the non-employees.  During the three months ended March 31, 2012, the Company awarded an aggregate of 189,557 shares and recognized a total expense of $126,916.
	Warrant Awards
	During the three months ended March 30, 2013, the Company recognized an expense of $2,760 for the warrants that were previously awarded during the year ended December 29, 2012.  The Company did not award any new warrants during the three months ended March 30, 2013.  As of March 30, 2013, there was $1,334 of total unrecognized compensation expense related to warrants awarded to the non-employee.
	For non-employee share-based compensation, the Company recognized share-based compensation expense of $65,056 in general and administrative expenses in the statement of operations for the three months ended March 30, 2013. The Company recognized $362,122 in share-based compensation expense for the three months ended March 31, 2012.

Warrants

Warrants	3 Months Ended
	Mar. 30, 2013
Warrants	'
Note 8. Warrants	'
	During the three months ended March 30, 2013, 3,414,283 warrants with an exercise price of $0.21 per share were exercised and the Company received proceeds of $716,999 from exercise of these warrants.  These warrants were issued during the year ended January 1, 2011 pursuant to a subscription agreement entered into by the holders of such warrants and the Company on April 22, 2010.
	In addition, during the three months ended March 30, 2013, 781,236 warrants issued during the year 2008 with an exercise price of $3.00 per share expired.
	At March 30, 2013, the following warrants were outstanding and exercisable:
	Warrants granted in connection with :	Weighted Average		Number Outstanding		Weighted Average
		Exercise Prices		And Exercisable		Remaining Contractual Life
				At March 30, 2013
	2008 Private placement equity offering	$	3		937,114	2.1 months
	2010 Private placement equity offering	$	0.21		4,389,281	1.7 months
	2012 Placement agent commission	$	0.85		285,000	16.1 months
	2012 Non-employee award	$	0.75		250,000	16.3 months
		$	0.71		5,861,395	3.1 months

Business_Segmentation

Business Segmentation	3 Months Ended
	Mar. 30, 2013
Business Segmentation	'
Note 9 .Business Segmentation	'
	Since the year ended December 29, 2012, the Company has generated considerable revenue from its recently acquired subsidiary, Spherix, which provides scientific and regulatory consulting.  As a result, the Company began segregating its financial results for Spherix, and has following three reportable segments.
		·	Core standards, contract services and ingredients segment includes supply of phytochemical reference standards, which are small quantities of plant-based compounds typically used to research an array of potential attributes, and reference materials, related contract services, and proprietary ingredients.
		·	Retail dietary supplement products segment which consist of the supply of the BluScience line of dietary supplement products containing the Company’s proprietary ingredients to various retail distribution channels.
		·	Scientific and regulatory consulting segment which consist of providing scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage potential health and regulatory risks.
	The “Other” classification includes corporate items not allocated by the Company to each reportable segment. Further, there are no intersegment sales that require elimination.  The Company evaluates performance and allocates resources based on reviewing gross margin by reportable segment.
	Three months ended March 30, 2013		Core Standards, Contract Services and Ingredients segment			Retail Dietary Supplement			Scientific and Regulatory Consulting segment			Other			Total (Restated, Note 2)
						Products segment (Restated, Note 2)
	Gross Sales		$	2,177,355		$	557,111		$	245,786		$	—		$	2,980,252
	Discounts and returns			(25,842	)		(617,396	)		(2,448	)		—			(645,686	)
	Net sales			2,151,513			(60,285	)		243,338			—			2,334,566
	Cost of sales			1,513,983			955			146,788			—			1,661,726
	Gross profit (loss)			637,530			(61,240	)		96,550			—			672,840
	Operating expenses:
	Sales and marketing			596,777			131,159			1,488			—			729,424
	General and administrative			—			—			—			1,359,901			1,359,901
	Operating expenses			596,777			131,159			1,488			1,359,901			2,089,325
	Operating income (loss)		$	40,753		$	(192,399	)	$	95,062		$	(1,359,901	)	$	(1,416,485	)
	Three months ended March 31, 2012		Core Standards, Contract Services and Ingredients segment			Retail Dietary			Scientific and Regulatory Consulting segment			Other			Total
						Supplement
						Products segment
	Gross Sales		$	1,871,718		$	2,179,426		$	—		$	—		$	4,051,144
	Promotions, discounts and returns			(16,970	)		(2,249,168	)		—			—			(2,266,138	)
	Net sales			1,854,748			(69,742	)		—			—			1,785,006
	Cost of sales			1,346,622			1,042,598			—			—			2,389,220
	Gross profit (loss)			508,126			(1,112,340	)		—			—			(604,214	)
	Operating expenses:
	Sales and marketing			474,944			1,383,718			—			—			1,858,662
	General and administrative			—			—			—			1,961,912			1,961,912
	Operating expenses			474,944			1,383,718			—			1,961,912			3,820,574
	Operating income (loss)		$	33,182		$	(2,496,058	)	$	—		$	(1,961,912	)		(4,424,788	)
	At March 30, 2013		Core Standards, Contract Services and Ingredients segment			Retail Dietary Supplement			Scientific and Regulatory Consulting segment			Other (Restated, Note 2)			Total (Restated, Note 2)
						Products segment
	Total assets		$	3,218,208		$	—		$	201,898		$	4,404,728		$	7,824,834
	At December 29, 2012		Core Standards, Contract Services and Ingredients segment			Retail Dietary Supplement			Scientific and Regulatory Consulting segment			Other			Total
						Products segment
	Total assets		$	3,542,355		$	4,331,866		$	72,573		$	1,087,727		$	9,034,521

Managements_Plans_for_Continui

Managements Plans for Continuing Operations	3 Months Ended
	Mar. 30, 2013
Managements Plans For Continuing Operations	'
Note 10. Managements Plans for Continuing Operations	'
	The Company has incurred a net loss of $1,424,072 for the three-month period ended March 30, 2013 and an operating loss of $1,416,485 for the three-month period ended March 30, 2013. One of the factors that contributed to this loss is share-based compensation expense. The Company’s share-based compensation expense totaled $351,590 for the three months ended March 30, 2013. In addition to the stock options granted to employees, the Company has been awarding shares of its common stock to non-employees as compensation of the services provided. The Company also incurred an operating loss of $192,399 from BluScience operations, without the gain on sale of BluScience consumer production line. Increase in trade accounts receivable allowance for possible future returns was the main reason for the loss from BluScience operations as the increase in allowance was treated as a reduction of revenue. Another factor that contributed to the loss is the investment in additional personnel and marketing expenses to implement its business plan to expand the line of proprietary ingredients. This has resulted in higher selling, marketing and patent related expenses compared to prior years. Management has also implemented additional strategic operational structure changes, which it believes, will allow the Company to achieve profitability with future growth without incurring significant additional overhead costs. Management’s anticipation of future growth is largely related to the demand of the line of proprietary ingredients offered by the Company.
	By curtailing certain expenditures, management believes it will be able to support operations of the Company with its current cash and cash from operations through December, 2013. In addition, although uncertain, the Company may have prospective collections of up to $1,333,334 from NeutriSci prior to December, 2013 from the sale of BluScience consumer product line. Also, as of March 30, 2013, the Company has 4,389,281 warrants outstanding with an exercise price of $0.21 per share. Assuming the full exercise of the outstanding warrants for cash, the Company would receive additional proceeds of $921,749. There can be no assurance that the holders of these warrants will exercise any of the outstanding warrants for cash, and the Company will not receive any proceeds from any of the outstanding warrants until they are exercised.
	If the Company determines that it shall require additional financing to further enable it to achieve its long-term strategic objectives, there can be no assurance that such financing will be available on terms favorable to it or at all. If adequate financing is not available, the Company will further delay, postpone or terminate product and service expansion and curtail certain selling, general and administrative operations. The inability to raise additional financing may have a material adverse effect on the future performance of the Company.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 30, 2013
Income Taxes	'
Note 11. Income Taxes	'
	At March 30, 2013 and December 29, 2012, the Company maintained a full valuation allowance against the entire net deferred income tax balance after considering relevant factors, including recent operating results, the likelihood of the utilization of net operating loss tax carry forwards, and the ability to generate future taxable income.  The Company expects to maintain a full valuation allowance on its entire net deferred tax assets in 2013, resulting in an effective tax rate of zero for the three months ended March 30, 2013.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 30, 2013
Subsequent Events [Abstract]	'
Note 12. Subsequent Events	'
	From March 31, 2013 through May 9, 2013, 2,314,283 of the warrants with an exercise price of $0.21 per share have been exercised and the Company received proceeds of $485,999 from the exercise of the warrants.  These warrants were issued during the year ended January 1, 2011, pursuant to the Subscription Agreement entered into by the Company on April 22, 2010.
	From March 31, 2013 through May 9, 2013, 250,000 of the stock options with an exercise price of $0.50 per share have been exercised and the Company received proceeds of $125,000.

Nature_of_Business_and_Signifi1

Nature of Business and Significant Accounting Policies (Policy)	3 Months Ended
	Mar. 30, 2013
Nature Of Business And Significant Accounting Policies Policy	'
Nature of business	'
	Nature of business:  The Company is a natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The Company supplies ingredients, phytochemical reference standards and related phytochemical products and services. On December 3, 2012, the Company acquired Spherix Consulting, Inc. (“Spherix”), which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage potential health and regulatory risks.  The Company provides these products and services at various terms.
Basis of presentation	'
	Basis of presentation:  The financial statements and accompanying notes have been prepared on a consolidated basis and reflect the consolidated financial position of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated from these financial statements. The Company's fiscal year ends on the Saturday closest to December 31, and the Company’s normal fiscal quarters end on the Saturday 13 weeks after the last fiscal year end or fiscal quarter end.  Every fifth or sixth fiscal year, the inclusion of an extra week occurs due to the Company’s floating year-end date.  The fiscal year 2014 will include 53 weeks instead of the normal 52 weeks.
Trade accounts receivable	'
	Trade accounts receivable:  Trade accounts receivable are carried at original invoice amount less an estimate made for doubtful receivables based on monthly and quarterly reviews of all outstanding amounts.  Management determines the allowance for doubtful accounts by identifying troubled accounts and by using historical experience applied to an aging of accounts.  The allowances for doubtful accounts for the periods ended March 30, 2013 and December 29, 2012 were $18,000 and $450,000, respectively.  Of the allowance amount of $450,000 for the period ended December 29, 2012, $433,000 represents a hold on the receivables placed by a retailer that carried the Company’s BluScience retail consumer line.  The hold was placed by the retailer as an offset in the event of future returns of the Company’s products and the hold was treated as a reduction of revenue. On March 28, 2013, the Company sold the BluScience retail consumer line to NeutriSci International Inc. (“NeutriSci”) and the related trade accounts receivable including the allowance have been transferred to NeutriSci. Trade accounts receivable are written off when deemed uncollectible.  Recoveries of trade accounts receivable previously written off are recorded when received.
Inventories	'
	Inventories: Inventories are comprised of raw materials, work-in-process and finished goods.  They are stated at the lower of cost, determined by the first-in, first-out method (FIFO) method, or market.  The inventory on the balance sheet is recorded net of valuation allowances of $217,000 and $366,000 for the periods ended March 30, 2013 and December 29, 2012, respectively.  Labor and overhead has been added to inventory that was manufactured or characterized by the Company.  On March 28, 2013, the Company sold the BluScience retail consumer line to NeutriSci and related dietary supplements inventory have been transferred to NeutriSci.  The amounts of major classes of inventory as of March 30, 2013 and December 29, 2012 are as follows:
		March 30,		December 29,
		2013		2012
	Reference standards	$	1,598,277	$	1,614,755
	Bulk ingredients		192,175		432,230
	Dietary supplements – raw materials		-		401,809
	Dietary supplements – work in process		-		465,253
	Dietary supplements – finished goods		-		2,657,257
			1,790,452		5,571,304
	Less valuation allowance		217,000		366,000
		$	1,573,452	$	5,205,304
Earnings per share	'
	Earnings per share: Potentially dilutive common shares consist of the incremental common shares issuable upon the exercise of common stock options and warrants for all periods.   For the three-month periods ended March 30, 2013 and March 31, 2012, the basic and diluted shares reported are equal because the common share equivalents are anti-dilutive due to the net loss. Below is a tabulation of the potentially dilutive securities that were “in the money” for the three- month periods ended March 30, 2013 and March 31, 2012.
		Three Months Ended
		30-Mar-13		31-Mar-12
	Basic weighted average common shares outstanding		94,626,120		84,706,196
	Warrants and options in the money, net		3,298,337		6,583,163
	Weighted average common shares outstanding assuming dilution		97,924,457		91,289,359
	Total warrants and options that were not “in the money” at March 30, 2013 and March 31, 2012 were 12,338,106 and 18,579,518, respectively.
Long-term investment in affiliate	'
	Long-term investment in affiliate: The Company accounts for its investment in affiliate under the equity method. The Company records equity method adjustments in gains (losses) on equity method investments, net, and may do so with up to a three-month lag, pending on the timely availability of financial information of the investee. Equity method adjustments include: our proportionate share of investee income or loss, gains or losses resulting from investee capital transactions, and other adjustments required by the equity method. The long-term investment in affiliate is subject to a periodic impairment review and is considered to be impaired when a decline in carrying value is judged to be other-than-temporary. Evidence of a loss in value might include (i) absence of an ability recover the carrying amount of the investment or (ii) inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment.

Restatement_of_Previously_Issu1

Restatement of Previously Issued Financial Statements (Tables)	3 Months Ended
	Mar. 30, 2013
Restatement Of Previously Issued Financial Statements Tables	'
Restatement	'
	The restatement adjustments to the previously issued financial statements for the three month period ended March 30, 2013 are as follows:
	ChromaDex Corporation and Subsidiaries
	Condensed Consolidated Balance Sheet (Unaudited)
	30-Mar-13
		Previously			Restatement			As Restated
		Reported			Adjustments
	Assets
	Current Assets
	Cash	$	966,576		$	—		$	966,576
	Trade receivables		986,370			—			986,370
	Non-trade receivable		500,000			—			500,000
	Note receivable, current		1,210,407			(1,210,407	)		—
	Inventories		1,573,452			—			1,573,452
	Prepaid expenses and other assets		453,198			—			453,198
	Total current assets		5,690,003			(1,210,407	)		4,479,596
	Leasehold Improvements and Equipment, net		980,792			—			980,792
	Other Noncurrent Assets
	Deposits		35,424			—			35,424
	Note receivable, less current		1,161,162			(1,161,162	)		—
	Long-term equity investment		2,678,832			(2,678,832	)		—
	Long-term investment in affiliate		—			2,157,804			2,157,804
	Intangible assets, net		171,218			—			171,218
	Total other noncurrent assets		4,046,636			(1,682,190	)		2,364,446
	Total assets	$	10,717,431		$	(2,892,597	)	$	7,824,834
	Liabilities and Stockholders' Equity
	Current Liabilities
	Accounts payable	$	2,376,208		$	—		$	2,376,208
	Accrued expenses		789,408			—			789,408
	Current maturities of capital lease obligations		98,841			—			98,841
	Customer deposits and other		314,468			—			314,468
	Deferred rent, current		66,772			—			66,772
	Total current liabilities		3,645,697			—			3,645,697
	Capital lease obligations, less current maturities		218,952			—			218,952
	Deferred rent, less current		118,508			—			118,508
	Stockholders' Equity
	Common stock		96,008			—			96,008
	Additional paid-in capital		34,886,353			—			34,886,353
	Accumulated deficit		(28,248,087	)		(2,892,597	)		(31,140,684	)
	Total stockholders' equity		6,734,274			(2,892,597	)		3,841,677
	Total liabilities and stockholders' equity	$	10,717,431		$	(2,892,597	)	$	7,824,834
	ChromaDex Corporation and Subsidiaries
	Condensed Consolidated Statement of Operations (Unaudited)
	For the Three Month Period Ended March 30, 2013
		Previously Reported			Restatement			As Restated
					Adjustments
	Sales	$	2,334,566		$	—		$	2,334,566
	Cost of sales		1,661,726			—			1,661,726
	Gross profit		672,840			—			672,840
	Operating expenses:
	Sales and marketing		729,424			—			729,424
	General and administrative		1,359,901			—			1,359,901
	Gain on sale of assets		(2,891,917	)		2,891,917			—
	Operating expenses		(802,592	)		2,891,917			2,089,325
	Operating income (loss)		1,475,432			(2,891,917	)		(1,416,485	)
	Nonoperating income (expense):
	Interest income		884			(680	)		204
	Interest expense		(7,791	)		—			(7,791	)
	Nonoperating expenses		(6,907	)		(680	)		(7,587	)
	Net income (loss)	$	1,468,525		$	(2,892,597	)	$	(1,424,072	)
	Basic net income (loss) per common share	$	0.02		$	(0.03	)	$	(0.02	)
	Diluted net income (loss) per common share	$	0.01		$	(0.03	)	$	(0.02	)
	Basic weighted average common shares outstanding		94,626,120			—			94,626,120
	Diluted weighted average common shares outstanding		97,924,457			(3,298,337	)		94,626,120
ChromaDex Corporation and Subsidiaries
Condensed Consolidated Statement of Cash Flows (Unaudited)
For the Three Month Period Ended March 30, 2013
	Previously Reported			Restatement			As Restated
				Adjustments
Cash Flows From Operating Activities
Net income (loss)	$	1,468,525		$	(2,892,597	)	$	(1,424,072	)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation of leasehold improvements and equipment		79,184			—			79,184
Amortization of intangibles		4,964			—			4,964
Share-based compensation expense		351,590			—			351,590
Gain on sale of assets		(2,891,917	)		2,891,917			—
Interest added to note receivable		(680	)		680			—
Changes in operating assets and liabilities:
Trade receivables		971,153			—			971,153
Inventories		164,322			—			164,322
Prepaid expenses and other assets		(86,181	)		—			(86,181	)
Accounts payable		(683,152	)		—			(683,152	)
Accrued expenses		(72,190	)		—			(72,190	)
Customer deposits and other		4,201			—			4,201
Deferred rent		(15,621	)		—			(15,621	)
Net cash used in operating activities		(705,802	)		—			(705,802	)
Cash Flows From Investing Activities
Purchases of leasehold improvements and equipment		(7,428	)		—			(7,428	)
Purchase of intangible assets		(40,000	)		—			(40,000	)
Proceeds from sale of assets		500,000			—			500,000
Net cash provided by investing activities		452,572			—			452,572
Cash Flows From Financing Activities
Proceeds from exercise of stock options		6,769			—			6,769
Proceeds from exercise of warrants		716,999			—			716,999
Principal payments on capital leases		(23,962	)		—			(23,962	)
Net cash provided by financing activities		699,806			—			699,806
Net increase in cash		446,576			—			446,576
Cash Beginning of Period		520,000			—			520,000
Cash Ending of Period	$	966,576		$	—		$	966,576

Nature_of_Business_and_Signifi2

Nature of Business and Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 30, 2013
Nature Of Business And Significant Accounting Policies Tables	'
Inventories	'
	The amounts of major classes of inventory as of March 30, 2013 and December 29, 2012 are as follows:
		March 30,		December 29,
		2013		2012
	Reference standards	$	1,598,277	$	1,614,755
	Bulk ingredients		192,175		432,230
	Dietary supplements – raw materials		-		401,809
	Dietary supplements – work in process		-		465,253
	Dietary supplements – finished goods		-		2,657,257
			1,790,452		5,571,304
	Less valuation allowance		217,000		366,000
		$	1,573,452	$	5,205,304
Earnings per share	'
	Below is a tabulation of the potentially dilutive securities that were “in the money” for the three- month periods ended March 30, 2013 and March 31, 2012.
		Three Months Ended
		30-Mar-13		31-Mar-12
	Basic weighted average common shares outstanding		94,626,120		84,706,196
	Warrants and options in the money, net		3,298,337		6,583,163
	Weighted average common shares outstanding assuming dilution		97,924,457		91,289,359

Sale_of_Product_Line_and_Inves1

Sale of Product Line and Investment in Affiliate (Tables)	3 Months Ended
	Mar. 30, 2013
Sale Of Product Line And Investment In Affiliate	'
Determination of carrying value	'
	The below table illustrates how the carrying value was determined.
		At March 28, 2013
	Assets transferred
	Trade receivables, less allowance for returns	$	(16,984	)
	Inventories		3,467,530
	Prepaid expenses and other assets		76,131
	Total assets transferred		3,526,677
	Liabilities transferred
	Accounts payable		368,873
	Total liabilities transferred		368,873
	Total net assets transferred	$	3,157,804
	Initial monetary consideration received
	Cash	$	500,000
	Non-trade receivable		500,000
	Total initial monetary consideration received	$	1,000,000
	Carrying Value of Long Term Investment in Affiliate	$	2,157,804

Leasehold_Improvements_and_Equ1

Leasehold Improvements and Equipment (Tables)	3 Months Ended
	Mar. 30, 2013
Leasehold Improvements And Equipment	'
Leasehold Improvements and Equipment	'
	Leasehold improvements and equipment consisted of the following:
		March 30,		December 29,
		2013		2012
	Laboratory equipment	$	2,563,238	$	2,439,688
	Leasehold improvements		403,971		403,971
	Computer equipment		363,739		363,739
	Furniture and fixtures		18,313		18,313
	Office equipment		7,877		7,877
	Construction in progress		106,080		106,080
			3,463,218		3,339,668
	Less accumulated depreciation		2,482,426		2,403,242
		$	980,792	$	936,426

Employee_ShareBased_Compensati1

Employee Share-Based Compensation (Tables)	3 Months Ended
	Mar. 30, 2013
Employee Share-Based Compensation Tables	'
Weighted average assumptions of stock options granted	'
	The table below outlines the weighted average assumptions for options granted to employees during the three months ended March 30, 2013.
	Three Months Ended March 30, 2013
	Volatility		32.64	%
	Expected dividends		0	%
	Expected term	6.1 years
	Risk-free rate		1.13	%
Service Period Based Stock Options	'
	The following table summarizes service period based stock options activity at March 30, 2013 and changes during the three months then ended:
					Weighted Average
							Remaining		Aggregate
		Number of			Exercise		Contractual		Intrinsic
		Shares			Price		Term		Value
	Outstanding at December 29, 2012		12,202,558		$	1.08
	Options Granted		230,000			0.63
	Options Exercised		(13,538	)		0.5
	Options Expired		(75,000	)		0.5
	Options Forfeited		(112,530	)		1.37
	Outstanding at March 30, 2013		12,231,490		$	1.08		8.09	$	217,915
	Exercisable at March 30, 2013		5,096,949		$	1.26		6.41	$	113,085
Performance Based Stock Options	'
	The following table summarizes performance based stock options activity at March 30, 2013 and changes during the three months then ended:
					Weighted Average
							Remaining		Aggregate
		Number of			Exercise		Contractual		Intrinsic
		Shares			Price		Term		Value
	Outstanding at December 29, 2012		145,834		$	1.59
	Options Granted		200,000			0.63
	Options Exercised		-			-
	Options Expired		-			-
	Options Forfeited		(45,834	)		1.59
	Outstanding at March 30, 2013		300,000		$	0.95		9.25	$	16,000
	Exercisable at March 30, 2013		45,834		$	1.59		8.1	$	-
Restricted stock awards granted to employees	'
	The following table summarizes activity of restricted stock awards granted to employees at March 30, 2013 and changes during the three months then ended:
					Weighted Average
					Award-Date
		Shares			Fair Value
	Unvested shares at December 29, 2012		500,000		$	0.69
	Granted		-			-
	Vested		-			-
	Forfeited		-			-
	Unvested shares at March 30, 2013		500,000		$	0.69
	Expected to Vest as of March 30, 2013		500,000		$	0.69

NonEmployee_ShareBased_Compens1

Non-Employee Share-Based Compensation (Tables)	3 Months Ended
	Mar. 30, 2013
Non-Employee Share-Based Compensation Tables	'
Non-Employee stock options	'
	The following table summarizes activity of stock options granted to non-employees at March 30, 2013 and changes during the three months then ended:
				Weighted Average
						Remaining		Aggregate
		Number of		Exercise		Contractual		Intrinsic
		Shares		Price		Term		Value
	Outstanding at December 29, 2012		1,097,300	$	1.23
	Options Granted		-		-
	Options Exercised		-		-
	Options Forfeited		-		-
	Outstanding at March 30, 2013		1,097,300	$	1.23		5.01	$	59,200
	Exercisable at March 30, 2013		1,096,675	$	1.23		5.01	$	59,069

Warrants_Tables

Warrants (Tables)	3 Months Ended
	Mar. 30, 2013
Warrants Tables	'
Warrants	'
	At March 30, 2013, the following warrants were outstanding and exercisable:
	Warrants granted in connection with :	Weighted Average		Number Outstanding		Weighted Average
		Exercise Prices		And Exercisable		Remaining Contractual Life
				At March 30, 2013
	2008 Private placement equity offering	$	3		937,114	2.1 months
	2010 Private placement equity offering	$	0.21		4,389,281	1.7 months
	2012 Placement agent commission	$	0.85		285,000	16.1 months
	2012 Non-employee award	$	0.75		250,000	16.3 months
		$	0.71		5,861,395	3.1 months

Business_Segmentation_Tables

Business Segmentation (Tables)	3 Months Ended
	Mar. 30, 2013
Business Segmentation Tables	'
Business Segmentation	'
	Three months ended March 30, 2013	Core Standards, Contract Services and Ingredients segment			Retail Dietary Supplement			Scientific and Regulatory Consulting segment			Other			Total (Restated, Note 2)
					Products segment (Restated, Note 2)
	Gross Sales	$	2,177,355		$	557,111		$	245,786		$	—		$	2,980,252
	Discounts and returns		(25,842	)		(617,396	)		(2,448	)		—			(645,686	)
	Net sales		2,151,513			(60,285	)		243,338			—			2,334,566
	Cost of sales		1,513,983			955			146,788			—			1,661,726
	Gross profit (loss)		637,530			(61,240	)		96,550			—			672,840
	Operating expenses:
	Sales and marketing		596,777			131,159			1,488			—			729,424
	General and administrative		—			—			—			1,359,901			1,359,901
	Operating expenses		596,777			131,159			1,488			1,359,901			2,089,325
	Operating income (loss)	$	40,753		$	(192,399	)	$	95,062		$	(1,359,901	)	$	(1,416,485	)
	Three months ended March 31, 2012	Core Standards, Contract Services and Ingredients segment			Retail Dietary			Scientific and Regulatory Consulting segment			Other			Total
					Supplement
					Products segment
	Gross Sales	$	1,871,718		$	2,179,426		$	—		$	—		$	4,051,144
	Promotions, discounts and returns		(16,970	)		(2,249,168	)		—			—			(2,266,138	)
	Net sales		1,854,748			(69,742	)		—			—			1,785,006
	Cost of sales		1,346,622			1,042,598			—			—			2,389,220
	Gross profit (loss)		508,126			(1,112,340	)		—			—			(604,214	)
	Operating expenses:
	Sales and marketing		474,944			1,383,718			—			—			1,858,662
	General and administrative		—			—			—			1,961,912			1,961,912
	Operating expenses		474,944			1,383,718			—			1,961,912			3,820,574
	Operating income (loss)	$	33,182		$	(2,496,058	)	$	—		$	(1,961,912	)		(4,424,788	)
	At March 30, 2013	Core Standards, Contract Services and Ingredients segment			Retail Dietary Supplement			Scientific and Regulatory Consulting segment			Other (Restated, Note 2)			Total (Restated, Note 2)
					Products segment
	Total assets	$	3,218,208		$	—		$	201,898		$	4,404,728		$	7,824,834
	At December 29, 2012	Core Standards, Contract Services and Ingredients segment			Retail Dietary Supplement			Scientific and Regulatory Consulting segment			Other			Total
					Products segment
	Total assets	$	3,542,355		$	4,331,866		$	72,573		$	1,087,727		$	9,034,521

Restatement_of_Previously_Issu2

Restatement of Previously Issued Financial Statements (Details) (USD $)	Mar. 30, 2013	Dec. 29, 2012	Mar. 31, 2012
Current Assets	'	'	'
Cash	$966,576	$520,000	$5,805,179
Trade receivables	986,370	1,940,539	'
Non-trade receivable	500,000	'	'
Inventories	1,573,452	5,205,304	'
Prepaid expenses and other assets	453,198	261,297	'
Total current assets	4,479,596	7,927,140	'
Leasehold Improvements and Equipment, net	980,792	936,426	'
Other Noncurrent Assets	'	'	'
Deposits	35,424	34,773	'
Long-term investment in affiliate (Note 4)	2,157,804	'	'
Intangible assets, net	171,218	136,182	'
Total other noncurrent assets	2,364,446	170,955	'
Total assets	7,824,834	9,034,521	'
Current Liabilities	'	'	'
Accounts payable	2,376,208	3,428,233	'
Accrued expenses	789,408	876,158	'
Current maturities of capital lease obligations	98,841	77,259	'
Customer deposits and other	314,468	310,267	'
Deferred rent, current	66,772	71,042	'
Total current liabilities	3,645,697	4,762,959	'
Capital lease obligations, less current maturities	218,952	148,374	'
Deferred rent, less current	118,508	129,859	'
Stockholders' Equity	'	'	'
Common stock	96,008	92,140	'
Additional paid-in capital	34,886,353	33,617,801	'
Accumulated deficit	-31,140,684	-29,716,612	'
Total stockholders' equity	3,841,677	3,993,329	'
Total liabilities and stockholders' equity	7,824,834	9,034,521	'
Scenario, Previously Reported [Member]	'	'	'
Current Assets	'	'	'
Cash	966,576	'	'
Trade receivables	986,370	'	'
Non-trade receivable	500,000	'	'
Note receivable, current	1,210,407	'	'
Inventories	1,573,452	'	'
Prepaid expenses and other assets	453,198	'	'
Total current assets	5,690,003	'	'
Leasehold Improvements and Equipment, net	980,792	'	'
Other Noncurrent Assets	'	'	'
Deposits	35,424	'	'
Note receivable, less current	1,161,162	'	'
Long-term equity investment	2,678,832	'	'
Long-term investment in affiliate (Note 4)	'	'	'
Intangible assets, net	171,218	'	'
Total other noncurrent assets	4,046,636	'	'
Total assets	10,717,431	'	'
Current Liabilities	'	'	'
Accounts payable	2,376,208	'	'
Accrued expenses	789,408	'	'
Current maturities of capital lease obligations	98,841	'	'
Customer deposits and other	314,468	'	'
Deferred rent, current	66,772	'	'
Total current liabilities	3,645,697	'	'
Capital lease obligations, less current maturities	218,952	'	'
Deferred rent, less current	118,508	'	'
Stockholders' Equity	'	'	'
Common stock	96,008	'	'
Additional paid-in capital	34,886,353	'	'
Accumulated deficit	-28,248,087	'	'
Total stockholders' equity	6,734,274	'	'
Total liabilities and stockholders' equity	10,717,431	'	'
Restatement Adjustment [Member]	'	'	'
Current Assets	'	'	'
Cash	'	'	'
Trade receivables	'	'	'
Non-trade receivable	'	'	'
Note receivable, current	-1,210,407	'	'
Inventories	'	'	'
Prepaid expenses and other assets	'	'	'
Total current assets	-1,210,407	'	'
Leasehold Improvements and Equipment, net	'	'	'
Other Noncurrent Assets	'	'	'
Deposits	'	'	'
Note receivable, less current	-1,161,162	'	'
Long-term equity investment	-2,678,832	'	'
Long-term investment in affiliate (Note 4)	2,157,804	'	'
Intangible assets, net	'	'	'
Total other noncurrent assets	-1,682,190	'	'
Total assets	-2,892,597	'	'
Current Liabilities	'	'	'
Accounts payable	'	'	'
Accrued expenses	'	'	'
Current maturities of capital lease obligations	'	'	'
Customer deposits and other	'	'	'
Deferred rent, current	'	'	'
Total current liabilities	'	'	'
Capital lease obligations, less current maturities	'	'	'
Deferred rent, less current	'	'	'
Stockholders' Equity	'	'	'
Common stock	'	'	'
Additional paid-in capital	'	'	'
Accumulated deficit	-2,892,597	'	'
Total stockholders' equity	-2,892,597	'	'
Total liabilities and stockholders' equity	-2,892,597	'	'
As Restated [Member]	'	'	'
Current Assets	'	'	'
Cash	966,576	'	'
Trade receivables	986,370	'	'
Non-trade receivable	500,000	'	'
Note receivable, current	'	'	'
Inventories	1,573,452	'	'
Prepaid expenses and other assets	453,198	'	'
Total current assets	4,479,596	'	'
Leasehold Improvements and Equipment, net	980,792	'	'
Other Noncurrent Assets	'	'	'
Deposits	35,424	'	'
Note receivable, less current	'	'	'
Long-term equity investment	'	'	'
Long-term investment in affiliate (Note 4)	2,157,804	'	'
Intangible assets, net	171,218	'	'
Total other noncurrent assets	2,364,446	'	'
Total assets	7,824,834	'	'
Current Liabilities	'	'	'
Accounts payable	2,376,208	'	'
Accrued expenses	789,408	'	'
Current maturities of capital lease obligations	98,841	'	'
Customer deposits and other	314,468	'	'
Deferred rent, current	66,772	'	'
Total current liabilities	3,645,697	'	'
Capital lease obligations, less current maturities	218,952	'	'
Deferred rent, less current	118,508	'	'
Stockholders' Equity	'	'	'
Common stock	96,008	'	'
Additional paid-in capital	34,886,353	'	'
Accumulated deficit	-31,140,684	'	'
Total stockholders' equity	3,841,677	'	'
Total liabilities and stockholders' equity	$7,824,834	'	'

Restatement_of_Previously_Issu3

Restatement of Previously Issued Financial Statements (Details 1) (USD $)	3 Months Ended
	Mar. 30, 2013	Mar. 31, 2012	Dec. 29, 2012
Sales	$2,334,566	$1,785,006	'
Cost of sales	1,661,726	2,389,220	'
Gross profit	672,840	-604,214	'
Operating expenses:	'	'	'
Sales and marketing	729,424	1,858,662	'
General and administrative	1,359,901	1,961,912	'
Operating expenses	2,089,325	3,820,574	'
Operating income (loss)	-1,416,485	-4,424,788	'
Nonoperating income (expense):	'	'	'
Interest income	204	1,199	'
Interest expense	-7,791	-8,264	'
Nonoperating expenses	7,587	7,065	'
Net income (loss)	-1,424,072	-4,431,853	'
Basic weighted average common shares outstanding	94,626,120	84,706,196	'
Cash Flows From Operating Activities	'	'	'
Net income (loss)	-1,424,072	-4,431,853	'
Adjustments to reconcile net income (loss) to net cash used in operating activities:	'	'	'
Depreciation of leasehold improvements and equipment	79,184	85,422	'
Amortization of intangibles	4,964	3,391	'
Share-based compensation expense	351,590	65,987	'
Gain on sale of assets	'	1,879	'
Changes in operating assets and liabilities:	'	'	'
Trade receivables	971,153	-676,991	'
Inventories	164,322	-1,145,295	'
Prepaid expenses and other assets	-86,181	519,481	'
Accounts payable	-683,152	816,215	'
Accrued expenses	-72,190	101,229	'
Customer deposits and other	4,201	20,109	'
Deferred rent	-15,621	-15,811	'
Net cash used in operating activities	-705,802	-4,656,237	'
Cash Flows From Investing Activities	'	'	'
Purchases of leasehold improvements and equipment	-7,428	-4,714	'
Purchase of intangible assets	-40,000	-2,000	'
Proceeds from sale of assets	500,000	'	'
Net cash provided by investing activities	452,572	-6,714	'
Cash Flows From Financing Activities	'	'	'
Proceeds from exercise of stock options	6,769	'	'
Proceeds from exercise of warrants	716,999	'	'
Principal payments on capital leases	-23,962	-22,260	'
Net cash provided by financing activities	699,806	10,047,978	'
Net increase in cash	446,576	5,385,027	'
Cash Ending of Period	966,576	5,805,179	520,000
Scenario, Previously Reported [Member]	'	'	'
Sales	2,334,566	'	'
Cost of sales	1,661,726	'	'
Gross profit	672,840	'	'
Operating expenses:	'	'	'
Sales and marketing	729,424	'	'
General and administrative	1,359,901	'	'
Gain on sale of assets	-2,891,917	'	'
Operating expenses	-802,592	'	'
Operating income (loss)	1,475,432	'	'
Nonoperating income (expense):	'	'	'
Interest income	884	'	'
Interest expense	-7,791	'	'
Nonoperating expenses	-6,907	'	'
Net income (loss)	1,468,525	'	'
Basic net income (loss) per common share	$0.02	'	'
Diluted net income (loss) per common share	$0.01	'	'
Basic weighted average common shares outstanding	94,626,120	'	'
Diluted weighted average common shares outstanding	97,924,457	'	'
Cash Flows From Operating Activities	'	'	'
Net income (loss)	1,468,525	'	'
Adjustments to reconcile net income (loss) to net cash used in operating activities:	'	'	'
Depreciation of leasehold improvements and equipment	79,184	'	'
Amortization of intangibles	4,964	'	'
Share-based compensation expense	351,590	'	'
Gain on sale of assets	-2,891,917	'	'
Interest added to note receivable	-680	'	'
Changes in operating assets and liabilities:	'	'	'
Trade receivables	971,153	'	'
Inventories	164,322	'	'
Prepaid expenses and other assets	-86,181	'	'
Accounts payable	-683,152	'	'
Accrued expenses	-72,190	'	'
Customer deposits and other	4,201	'	'
Deferred rent	-15,621	'	'
Net cash used in operating activities	-705,802	'	'
Cash Flows From Investing Activities	'	'	'
Purchases of leasehold improvements and equipment	-7,428	'	'
Purchase of intangible assets	-40,000	'	'
Proceeds from sale of assets	500,000	'	'
Net cash provided by investing activities	452,572	'	'
Cash Flows From Financing Activities	'	'	'
Proceeds from exercise of stock options	6,769	'	'
Proceeds from exercise of warrants	716,999	'	'
Principal payments on capital leases	-23,962	'	'
Net cash provided by financing activities	699,806	'	'
Net increase in cash	446,576	'	'
Cash Beginning of Period	520,000	'	'
Cash Ending of Period	966,576	'	'
Restatement Adjustment [Member]	'	'	'
Sales	'	'	'
Cost of sales	'	'	'
Gross profit	'	'	'
Operating expenses:	'	'	'
Sales and marketing	'	'	'
General and administrative	'	'	'
Gain on sale of assets	2,891,917	'	'
Operating expenses	2,891,917	'	'
Operating income (loss)	-2,891,917	'	'
Nonoperating income (expense):	'	'	'
Interest income	-680	'	'
Interest expense	'	'	'
Nonoperating expenses	-680	'	'
Net income (loss)	-2,892,597	'	'
Basic net income (loss) per common share	($0.03)	'	'
Diluted net income (loss) per common share	($0.03)	'	'
Basic weighted average common shares outstanding	'	'	'
Diluted weighted average common shares outstanding	-3,298,337	'	'
Cash Flows From Operating Activities	'	'	'
Net income (loss)	-2,892,597	'	'
Adjustments to reconcile net income (loss) to net cash used in operating activities:	'	'	'
Depreciation of leasehold improvements and equipment	'	'	'
Amortization of intangibles	'	'	'
Share-based compensation expense	'	'	'
Gain on sale of assets	2,891,917	'	'
Interest added to note receivable	680	'	'
Changes in operating assets and liabilities:	'	'	'
Trade receivables	'	'	'
Inventories	'	'	'
Prepaid expenses and other assets	'	'	'
Accounts payable	'	'	'
Accrued expenses	'	'	'
Customer deposits and other	'	'	'
Deferred rent	'	'	'
Net cash used in operating activities	'	'	'
Cash Flows From Investing Activities	'	'	'
Purchases of leasehold improvements and equipment	'	'	'
Purchase of intangible assets	'	'	'
Proceeds from sale of assets	'	'	'
Net cash provided by investing activities	'	'	'
Cash Flows From Financing Activities	'	'	'
Proceeds from exercise of stock options	'	'	'
Proceeds from exercise of warrants	'	'	'
Principal payments on capital leases	'	'	'
Net cash provided by financing activities	'	'	'
Net increase in cash	'	'	'
Cash Beginning of Period	'	'	'
Cash Ending of Period	'	'	'
As Restated [Member]	'	'	'
Sales	2,334,566	'	'
Cost of sales	1,661,726	'	'
Gross profit	672,840	'	'
Operating expenses:	'	'	'
Sales and marketing	729,424	'	'
General and administrative	1,359,901	'	'
Gain on sale of assets	'	'	'
Operating expenses	2,089,325	'	'
Operating income (loss)	-1,416,485	'	'
Nonoperating income (expense):	'	'	'
Interest income	204	'	'
Interest expense	-7,791	'	'
Nonoperating expenses	-7,587	'	'
Net income (loss)	-1,424,072	'	'
Basic net income (loss) per common share	($0.02)	'	'
Diluted net income (loss) per common share	($0.02)	'	'
Basic weighted average common shares outstanding	94,626,120	'	'
Diluted weighted average common shares outstanding	94,626,120	'	'
Cash Flows From Operating Activities	'	'	'
Net income (loss)	-1,424,072	'	'
Adjustments to reconcile net income (loss) to net cash used in operating activities:	'	'	'
Depreciation of leasehold improvements and equipment	79,184	'	'
Amortization of intangibles	4,964	'	'
Share-based compensation expense	351,590	'	'
Gain on sale of assets	'	'	'
Interest added to note receivable	'	'	'
Changes in operating assets and liabilities:	'	'	'
Trade receivables	971,153	'	'
Inventories	164,322	'	'
Prepaid expenses and other assets	-86,181	'	'
Accounts payable	-683,152	'	'
Accrued expenses	-72,190	'	'
Customer deposits and other	4,201	'	'
Deferred rent	-15,621	'	'
Net cash used in operating activities	-705,802	'	'
Cash Flows From Investing Activities	'	'	'
Purchases of leasehold improvements and equipment	-7,428	'	'
Purchase of intangible assets	-40,000	'	'
Proceeds from sale of assets	500,000	'	'
Net cash provided by investing activities	452,572	'	'
Cash Flows From Financing Activities	'	'	'
Proceeds from exercise of stock options	6,769	'	'
Proceeds from exercise of warrants	716,999	'	'
Principal payments on capital leases	-23,962	'	'
Net cash provided by financing activities	699,806	'	'
Net increase in cash	446,576	'	'
Cash Beginning of Period	520,000	'	'
Cash Ending of Period	$966,576	'	'

Nature_of_Business_and_Signifi3

Nature of Business and Significant Accounting Policies (Details) (USD $)	Mar. 30, 2013	Dec. 29, 2012
Inventories	'	'
Reference standards	$1,598,277	$1,614,755
Bulk ingredients	192,175	432,230
Dietary supplements - raw materials	'	401,809
Dietary supplements - work in process	'	465,253
Dietary supplements - finished goods	'	2,657,257
Inventory-gross	1,790,452	5,571,304
Less valuation allowance	217,000	366,000
Inventory-net	$1,573,452	$5,205,304

Nature_of_Business_and_Signifi4

Nature of Business and Significant Accounting Policies (Details 1)	3 Months Ended
	Mar. 30, 2013	Mar. 31, 2012
Earnings per share	'	'
Basic weighted average common shares outstanding	94,626,120	84,706,196
Warrants and options in the money, net	3,298,337	6,583,163
Weighted average common shares outstanding assuming dilution	97,924,457	91,289,359

Nature_of_Business_and_Signifi5

Nature of Business and Significant Accounting Policies (Details Narrative) (USD $)	Mar. 30, 2013	Dec. 29, 2012
Nature Of Business And Significant Accounting Policies Details Narrative	'	'
Inventory valuation allowances	$217,000	$366,000
Not in the money warrants and options	12,338,106	18,579,518
Hold on receivable amount	'	433,000
Allowance for doubtful accounts	$18,000	$450,000

Sale_of_Product_Line_and_Inves2

Sale of Product Line and Investment in Affiliate (Details) (USD $)	Mar. 28, 2013
Assets transferred	'
Trade receivables, less allowance for returns	($16,984)
Inventories	3,467,530
Prepaid expenses and other assets	76,131
Total assets transferred	3,526,677
Liabilities transferred	'
Accounts payable	368,873
Total liabilities transferred	368,873
Total net assets transferred	3,157,804
Initial monetary consideration received	'
Cash	500,000
Non-trade receivable	500,000
Total initial monetary consideration received	1,000,000
Carrying Value of Long Term Investment in Affiliate	$2,157,804

Sale_of_Product_Line_and_Inves3

Sale of Product Line and Investment in Affiliate (Details Narrative) (USD $)	Mar. 28, 2013	Mar. 30, 2013
		NeutriSci [Member]
Sale transaction value	'	$3,157,804
Deposit	'	250,000
Closing payment	'	250,000
Additional payment amount	'	500,000
Secured note	'	2,500,000
Convertible shares	'	625,000
Quarterly installment	'	416,667
Series I preferres shares issued	'	669,708
Series I conversion into Class A Common Shares	'	2,678,832
Class A common percent of deemed shares	'	19.00%
Class A price per share	'	$1
Royalty due to company on future net sales, rate	'	6.00%
Carrying value, equity investment, beginning balance	2,157,804	2,157,804
Cash payment received	'	$500,000
Series I Conversion rate per share	'	$4

Leasehold_Improvements_and_Equ2

Leasehold Improvements and Equipment (Details) (USD $)	Mar. 30, 2013	Dec. 29, 2012
Leasehold Improvements And Equipment Details	'	'
Laboratory equipment	$2,563,238	$2,439,688
Leasehold improvements	403,971	403,971
Computer equipment	363,739	363,739
Furniture and fixtures	18,313	18,313
Office equipment	7,877	7,877
Construction in progress	106,080	106,080
Leasehold Improvements and Equipment-gross	3,463,218	3,339,668
Less accumulated depreciation	2,482,426	2,403,242
Leasehold Improvements and Equipment-net	$980,792	$936,426

Employee_ShareBased_Compensati2

Employee Share-Based Compensation (Details) (Options [Member])	3 Months Ended
	Mar. 30, 2013
Options [Member]	'
Volatility	32.64%
Expected dividends	0.00%
Expected term	'6 years 1 month 6 days
Risk-free rate	1.13%

Employee_ShareBased_Compensati3

Employee Share-Based Compensation (Details 1) (ServicePeriodBasedStockOptions [Member], USD $)	3 Months Ended
	Mar. 30, 2013
ServicePeriodBasedStockOptions [Member]	'
Number of Shares	'
Outstanding at December 29, 2012	12,202,558
Options Granted	230,000
Options Exercised	-13,538
Options Expired	-75,000
Options Forfeited	-112,530
Outstanding at March 30, 2013	12,231,490
Exercisable at March 30, 2013	5,096,949
Weighted Average Exercise Price	'
Outstanding at December 29, 2012	$1.08
Options Granted	$0.63
Options Exercised	$0.50
Options Expired	$0.50
Options Forfeited	$1.37
Outstanding at March 30, 2013	$1.08
Exercisable at March 30, 2013	$1.26
Weighted Average Remaining Contractual Term	'
Outstanding at March 30, 2013	'8 years 1 month 2 days
Exercisable at March 30, 2013	'6 years 4 months 27 days
Aggregate Intrinsic Value	'
Outstanding at March 30, 2013	$217,915
Exercisable at March 30, 2013	$113,085

Employee_ShareBased_Compensati4

Employee Share-Based Compensation (Details 2) (PerformanceShares [Member], USD $)	3 Months Ended
	Mar. 30, 2013
PerformanceShares [Member]	'
Summary of performance based stock option activity- Shares	'
Outstanding at December 29, 2012	145,834
Options Granted	200,000
Options Exercised	'
Options Expired	'
Options Forfeited	-45,834
Outstanding at March 30, 2013	300,000
Exercisable at March 30, 2013	45,834
Weighted Average Exercise Price	'
Outstanding at December 29, 2012	$1.59
Options Granted	$0.63
Options Exercised	'
Options Expired	'
Options Forfeited	$1.59
Outstanding at March 30, 2013	$0.95
Exercisable at March 30, 2013	$1.59
Weighted Average Remaining Contractual Term	'
Outstanding at March 30, 2013	'9 years 3 months
Exercisable at March 30, 2013	'8 years 1 month 6 days
Aggregate Intrinsic Value	'
Outstanding at March 30, 2013	$16,000
Exercisable at March 30, 2013	'

Employee_ShareBased_Compensati5

Employee Share-Based Compensation (Details 3) (Restricted Stock [Member], USD $)	3 Months Ended
	Mar. 30, 2013
Restricted Stock [Member]	'
Summary of activity of restricted stock awards granted to employees- Shares	'
Unvested shares at December 29, 2012	500,000
Granted	'
Vested	'
Forfeited	'
Unvested shares at March 30, 2013	500,000
Expected to Vest as of March 30, 2013	500,000
Weighted Average Award-Date Fair Value	'
Unvested shares at December 29, 2012	$0.69
Granted	'
Vested	'
Forfeited	'
Unvested shares at March 30, 2013	$0.69
Expected to Vest as of March 30, 2013	$0.69

Employee_Share_Based_Compensat

Employee Share Based Compensation (Details Narrative) (USD $)	3 Months Ended
	Mar. 30, 2013	Mar. 31, 2012
GeneralAndAdministrativeExpense [Member]	'	'
Recognized share based compensation expense (income)	$286,534	($296,135)
Options [Member]	'	'
Expiration dates for stock options not exceeds	'10 years	'
Authorized stock options	20.00%	'
Remaining amount available for issuance	6,232,513	'
Unrecognized compensation expense	2,201,293	'
Cost is expected to be recognized over a weighted average period	'P2Y4M20D	'
Realized tax benefit from stock options	0	'
ServicePeriodBasedStockOptions [Member]	'	'
Closing stock price	$0.71	'
Weighted average fair value of options granted	$0.22	$0.31
Fair value of options exercised	2,437	'
PerformanceShares [Member]	'	'
Closing stock price	$0.71	'
Weighted average fair value of options granted	$0.22	'
Restricted Stock [Member]	'	'
Unrecognized compensation expense	$0	'

NonEmployee_ShareBased_Compens2

Non-Employee Share-Based Compensation (Details) (USD $)	3 Months Ended
	Mar. 30, 2013
Non-Employee Share-Based Compensation- Shares	'
Outstanding at December 29, 2012	1,097,300
Options Granted	'
Options Exercised	'
Options Forfeited	'
Outstanding at March 30, 2013	1,097,300
Exercisable at March 30, 2013	1,096,675
Weighted Average Exercise Price	'
Outstanding at December 29, 2012	$1.23
Options Granted	'
Options Exercised	'
Options Forfeited	'
Outstanding at March 30, 2013	$1.23
Exercisable at March 30, 2013	$1.23
Weighted Average Remaining Contractual Term	'
Outstanding at March 30, 2013	'5 years 6 months 4 days
Exercisable at March 30, 2013	'5 years 6 months 4 days
Aggregate Intrinsic Value	'
Outstanding at March 30, 2013	$59,200
Exercisable at March 30, 2013	$59,069

NonEmployee_ShareBased_Compens3

Non-Employee Share-Based Compensation (Details Textuals) (USD $)	3 Months Ended
	Mar. 30, 2013	Mar. 31, 2012
NonEmployeeShareBasedCompensation [Member] | Stock Options [Member]	'	'
Unrecognized expense	$219	'
Closing stock price	$0.71	'
Cost recognized period	'1 month 13 days	'
NonEmployeeShareBasedCompensation [Member] | StockAward [Member]	'	'
Issued during the period	440,000	189,557
Share-based compensation expense	62,178	126,916
Unrecognized compensation expense	204,746	'
NonEmployeeSharedBasedCompensation [Member] | WarrantAwardMember	'	'
Share-based compensation expense	2,760	'
Unrecognized compensation expense	1,334	'
NonEmployeeSharedBasedCompensation [Member] | GeneralAndAdministrativeExpenses [Member]	'	'
Share-based compensation expense	$65,056	$362,122

Warrants_Details

Warrants (Details) (USD $)	Mar. 30, 2013
PrivatePlacementEquityOffering2008Member	'
Warrants outstanding and exercisable	'
Weighted Average Exercise Prices	$3
Number Outstanding And Exercisable At March 30, 2013	937,114
Weighted Average Remaining Contractual Life	'2 months 3 days
PrivatePlacementEquityOffering2010Member	'
Warrants outstanding and exercisable	'
Weighted Average Exercise Prices	$0.21
Number Outstanding And Exercisable At March 30, 2013	4,389,281
Weighted Average Remaining Contractual Life	'1 month 21 days
PlacementAgentCommission2012Member	'
Warrants outstanding and exercisable	'
Weighted Average Exercise Prices	$0.85
Number Outstanding And Exercisable At March 30, 2013	285,000
Weighted Average Remaining Contractual Life	'1 year 4 months 3 days
NonEmployeeAward2010Member	'
Warrants outstanding and exercisable	'
Weighted Average Exercise Prices	$0.75
Number Outstanding And Exercisable At March 30, 2013	250,000
Weighted Average Remaining Contractual Life	'1 year 4 months 9 days
TotalMember	'
Warrants outstanding and exercisable	'
Weighted Average Exercise Prices	$0.71
Number Outstanding And Exercisable At March 30, 2013	5,861,395
Weighted Average Remaining Contractual Life	'3 months 3 days

Warrants_Details_Narrative

Warrants (Details Narrative) (USD $)	3 Months Ended
	Mar. 30, 2013	Mar. 31, 2012
Warrants Details Narrative	'	'
Proceeds from exercise of warrants	$716,999	'
exercise of warrants, shares	3,414,283	'
Exercise price of warrant	$0.21	'
Warrants expired	781,236	'
Exercise price of warrants expired	$3	'

Business_Segmentation_Details

Business Segmentation (Details) (USD $)	3 Months Ended
	Mar. 30, 2013	Mar. 31, 2012
Gross Sales	$2,980,252	$4,051,144
Promotions, discounts and returns	-645,686	-2,266,138
Net sales	2,334,566	1,785,006
Cost of sales	1,661,726	2,389,220
Gross profit (loss)	672,840	-604,214
Sales and marketing	729,424	1,858,662
General and Administrative	1,359,901	1,961,912
Operating expenses	2,089,325	3,820,574
Operating income (loss)	-1,416,485	-4,424,788
CoreStandardsContractServices [Member]	'	'
Gross Sales	2,177,355	1,871,718
Promotions, discounts and returns	-25,842	-16,970
Net sales	2,151,513	1,854,748
Cost of sales	1,513,983	1,346,622
Gross profit (loss)	637,530	508,126
Sales and marketing	596,777	474,944
General and Administrative	'	'
Operating expenses	596,777	474,944
Operating income (loss)	40,753	33,182
RetailDietarySupp [Member]	'	'
Gross Sales	557,111	2,179,426
Promotions, discounts and returns	-617,396	-2,249,168
Net sales	-60,285	-69,742
Cost of sales	955	1,042,598
Gross profit (loss)	-61,240	-1,112,340
Sales and marketing	131,159	1,383,718
General and Administrative	'	'
Operating expenses	131,159	1,383,718
Operating income (loss)	-192,399	-2,496,058
ScientificRegulatory [Member]	'	'
Gross Sales	245,786	'
Promotions, discounts and returns	-2,448	'
Net sales	243,338	'
Cost of sales	146,788	'
Gross profit (loss)	96,550	'
Sales and marketing	1,488	'
General and Administrative	'	'
Operating expenses	1,488	'
Operating income (loss)	95,062	'
OtherSegment [Member]	'	'
Gross Sales	'	'
Promotions, discounts and returns	'	'
Net sales	'	'
Cost of sales	'	'
Gross profit (loss)	'	'
Sales and marketing	'	'
General and Administrative	1,359,901	1,961,912
Operating expenses	1,359,901	1,961,912
Operating income (loss)	($1,359,901)	($1,961,912)

Business_Segmentation_Details2

Business Segmentation (Details2) (USD $)	Mar. 30, 2013	Dec. 29, 2012
Total assets	$7,824,834	$9,034,521
CoreStandardsContractServices [Member]	'	'
Total assets	3,218,208	3,542,355
RetailDietarySupp [Member]	'	'
Total assets	'	4,331,866
ScientificRegulatory [Member]	'	'
Total assets	201,898	72,573
OtherSegment [Member]	'	'
Total assets	$4,404,728	$1,087,727

Managements_Plans_for_Continui1

Management's Plans for Continuing Operations (Details Textuals) (USD $)	3 Months Ended
	Mar. 30, 2013	Mar. 31, 2012
Management's Plans for Continuing Operations	'	'
Net loss	($1,424,072)	($4,431,853)
Operating loss	-1,416,485	-4,424,788
Share based compensation expense	351,590	'
Operating loss from BluScience	192,399	'
Additional proceeds expected in 2013 from sale of BluScience	1,333,334	'
Warrants outstanding	4,389,281	'
Exercise price	$0.21	'
Additional proceeds expected from warrant exercise	$921,749	'

Subsequent_Events_Details_Narr

Subsequent Events (Details Narrative) (USD $)	1 Months Ended
	9-May-13
Subsequent Events [Abstract]	'
Warrants exercised	2,314,283
Exercise price per share, warrant	$0.21
Proceeds from exercise of warrants	$485,999
Options exercised	250,000
Exercise price per share, option	$0.50
Proceeds from exercise of options	$125,000